It's true it's a great drug and everything, but it's not enough to pick up a whole company.

We think there could be positive pipeline news over the near term.

They've been in a slump and they remain so.

That is a big market -- the diabetic market is huge. It's a good thing, if there's a new indication (for the drug). But I'm not buying the stock on the basis of this.

No leadership will just present everything that a company offers.

We were hoping to build a small, profitable company. And of course, what we've done is build a large, unprofitable company.